Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target
Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. ORKA | 0.00 |
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:
ORKA) with a Buy and maintains $200 price target.
